174 related articles for article (PubMed ID: 38106820)
41. A cross-sectional study to describe the spectrum of ocular manifestations and risk factors of mucormycosis presenting to a tertiary hospital of East India.
Raj A; Nishant P; Sadhukhan K; Saha BC; Sinha U; Kokkayil P; Gupta A; Kumar A; Tiwari P
Indian J Ophthalmol; 2023 Jan; 71(1):249-256. PubMed ID: 36588245
[TBL] [Abstract][Full Text] [Related]
42. Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic.
Fouad YA; Abdelaziz TT; Askoura A; Saleh MI; Mahmoud MS; Ashour DM; Ashour MM
Front Med (Lausanne); 2021; 8():645270. PubMed ID: 34124087
[No Abstract] [Full Text] [Related]
43. Surgical & medical management of ROCM (Rhino-orbito-cerebral mucormycosis) epidemic in COVID-19 era and its outcomes - a tertiary care center experience.
Soni K; Das A; Sharma V; Goyal A; Choudhury B; Chugh A; Kumar D; Yadav T; Jain V; Agarwal A; Garg M; Bhatnagar K; Elhence P; Bhatia PK; Garg MK; Misra S
J Mycol Med; 2022 May; 32(2):101238. PubMed ID: 34979299
[TBL] [Abstract][Full Text] [Related]
44. COVID-19-Associated Mucormycosis in a Tertiary Care Hospital in India: A Case Series.
Singh S; Basera P; Anand A; Ozair A
Cureus; 2022 Aug; 14(8):e27906. PubMed ID: 36110469
[TBL] [Abstract][Full Text] [Related]
45. Spectrum of Mucormycosis Before and During COVID-19: Epidemiology, Diagnosis, and Current Therapeutic Interventions.
Mansoor S; Ahmed TI; Happa K; Sultan M; Manhas S; Shamas S
Curr Fungal Infect Rep; 2022; 16(4):131-142. PubMed ID: 35967987
[TBL] [Abstract][Full Text] [Related]
46. Various Treatment Modalities in COVID-19 Associated Facial Mucormycosis and the Need for its Surgical Management: A Systematic Review.
Chopra S; Setiya S; Waknis PP; Kale L; Tidke S
J Maxillofac Oral Surg; 2023 Mar; ():1-22. PubMed ID: 37362874
[TBL] [Abstract][Full Text] [Related]
47. Rising Incidence of Post Covid Rhinocerebral Mucormycosis: An Otolaryngologists Prospective.
Sahni D; Singh P; Kaur R; Aggarwal S; Kaur A
Indian J Otolaryngol Head Neck Surg; 2023 May; 75(4):1-9. PubMed ID: 37362131
[TBL] [Abstract][Full Text] [Related]
48. Management outcomes of mucormycosis in COVID-19 patients: A preliminary report from a tertiary care hospital.
Kumari A; Rao NP; Patnaik U; Malik V; Tevatia MS; Thakur S; Jaydevan J; Saxena P
Med J Armed Forces India; 2021 Jul; 77(Suppl 2):S289-S295. PubMed ID: 34334896
[TBL] [Abstract][Full Text] [Related]
49. Mucormycosis in COVID-19 patients.
Sundaram N; Bhende T; Yashwant R; Jadhav S; Jain A
Indian J Ophthalmol; 2021 Dec; 69(12):3728-3733. PubMed ID: 34827032
[TBL] [Abstract][Full Text] [Related]
50. Uncontrolled diabetes mellitus exacerbated by COVID-19-induced inflammation is the risk factor for COVID-19-associated rhino-orbito-cerebral mucormycosis: A matched pair case-control study.
Karat S; Lobo AC; Satish D; Devaraj R; Manjooran RR; Nithyanandam S
Indian J Ophthalmol; 2022 Aug; 70(8):3096-3101. PubMed ID: 35918980
[TBL] [Abstract][Full Text] [Related]
51. A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19.
Waizel-Haiat S; Guerrero-Paz JA; Sanchez-Hurtado L; Calleja-Alarcon S; Romero-Gutierrez L
Cureus; 2021 Feb; 13(2):e13163. PubMed ID: 33575155
[TBL] [Abstract][Full Text] [Related]
52. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients.
Bansal SB; Rana A; Babras M; Yadav D; Jha P; Jain M; Sethi SK
Transpl Infect Dis; 2022 Apr; 24(2):e13777. PubMed ID: 34932870
[TBL] [Abstract][Full Text] [Related]
53. Management Challenge of Rhino-Orbito-Cerebral Mucormycosis in Covid 19 Era: A Prospective Observational Study.
Pippal SK; Kumar D; Ukawat L
Indian J Otolaryngol Head Neck Surg; 2022 Oct; 74(Suppl 2):3485-3491. PubMed ID: 34722223
[TBL] [Abstract][Full Text] [Related]
54. Orbital Mucormycosis: Understanding the Deadly Fungus Sweeping the Globe.
Farooq S; Khan NA; Singh A; Khan A; Sharma P; Meena R; Jakhar A; Kumar M; Kochar A
Cureus; 2023 Jun; 15(6):e41010. PubMed ID: 37519583
[TBL] [Abstract][Full Text] [Related]
55. COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases.
Özbek L; Topçu U; Manay M; Esen BH; Bektas SN; Aydın S; Özdemir B; Khostelidi SN; Klimko N; Cornely O; Zakhour J; Kanj SS; Seidel D; Hoenigl M; Ergönül Ö
Clin Microbiol Infect; 2023 Jun; 29(6):722-731. PubMed ID: 36921716
[TBL] [Abstract][Full Text] [Related]
56. The Study of Clinical Profile of Patients With Mucormycosis During COVID-19 Pandemic in Tertiary Care Hospital.
Kumar S; Anita ; Dev A; Kumar A; Kumar Nayan S; Singh S
Cureus; 2023 Oct; 15(10):e47065. PubMed ID: 38021649
[TBL] [Abstract][Full Text] [Related]
57. Determinants of stroke in patients with rhino cerebral mucormycosis seen during the second wave of COVID-19 pandemic: A prospective cohort study.
Pandey S; Malhotra HS; Garg RK; Sharma K; Rizvi I; Kumar S; Kumar N; Uniyal R; Sharma PK; Gupta P; Jain A; Reddy DH
J Infect Public Health; 2022 Nov; 15(11):1265-1269. PubMed ID: 36272391
[TBL] [Abstract][Full Text] [Related]
58. Rise of the phoenix: Mucormycosis in COVID-19 times.
Ravani SA; Agrawal GA; Leuva PA; Modi PH; Amin KD
Indian J Ophthalmol; 2021 Jun; 69(6):1563-1568. PubMed ID: 34011742
[TBL] [Abstract][Full Text] [Related]
59. A case series of post COVID-19 mucormycosis-a neurological prospective.
Roushdy T; Hamid E
Egypt J Neurol Psychiatr Neurosurg; 2021; 57(1):100. PubMed ID: 34335016
[TBL] [Abstract][Full Text] [Related]
60. Mucor in a Viral Land: A Tale of Two Pathogens.
Sen M; Lahane S; Lahane TP; Parekh R; Honavar SG
Indian J Ophthalmol; 2021 Feb; 69(2):244-252. PubMed ID: 33463566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
